Introduction {#s0005}
============

Cancer is one of the leading causes of death worldwide. According to cancer statistics from the National Cancer Institute, in 2012, there were 14 million new cases and 8.2 million cancer-related deaths worldwide, and the number of cancer cases is projected to increase globally by 50% in 2030 [@bb0005]. Despite advances in chemotherapeutic treatments, most patients with refractory cancer develop resistance to these therapies and have few treatment options.

Next-generation sequencing (NGS) technologies have led to a comprehensive understanding of cancer genomes and are increasingly being used for both clinical and research applications. NGS testing of clinically relevant cancer-related genes has enabled cancer patients to access targeted therapies and predict response to treatments. Many research groups have established NGS testing for treatment decision making, and currently active clinical trials, such as umbrella and basket trials, have shown that the use of NGS testing results in better outcomes for patients than those in patients not using it [@bb0010], [@bb0015], [@bb0020].

Therefore, this study was undertaken to assess whether NGS testing is reliable and useful for decision making in the clinic for patients with refractory solid tumors in our institute. In this pilot study, 25 patients were enrolled, and their tissues were sequenced using a panel of 83 cancer-related genes.

Methods {#s0010}
=======

Patients {#s0015}
--------

Patients with refractory solid tumors were enrolled in this study. The study was approved by the institutional review board of Pusan National University Hospital. All study participants provided written informed consent before being enrolled in the study. The criteria for participation included the following: patients with pathologically confirmed cancer; patients with recurrent/metastatic solid tumors who did not respond to standard therapy; patients ≥18 years old; Eastern Cooperative Oncology Group performance status of 0, 1, or 2; presence of enough tumor tissue for targeted sequencing; measurable disease in accordance with the Response Evaluation Criteria version 1.1; life expectancy ≥3 months; adequate bone marrow function (neutrophils ≥1.5 × 10^9^/l, platelets ≥100 × 10^9^/l; Hb \>10 g/dl); adequate liver function \[aspartate aminotransferase/alanine aminotransferase ≤5× upper limit of normal (ULN), bilirubin ≤2× ULN, albumin \>25 g/l\]; and adequate renal function (creatinine ≤2× ULN). The exclusion criteria were alcohol or substance abuse; pregnant or breast-feeding women; patients with cardiac, renal, or hepatic dysfunction; patients with infectious, neurological, or psychiatric disorders that may affect the study\'s results; and patients with uncontrollable elevation of intracranial pressure.

Targeted Sequencing {#s0020}
-------------------

A targeting panel was used to capture the target regions of 83 cancer-related genes for the detection of single nucleotide variants (SNVs), insertion/deletions (INDELs), and copy number variations (CNVs), including all coding exons of the following 72 genes: *ABL1, AKT1, AKT2, AKT3, ALK, APC, ARID1A, ARID1B, ARID2, ATM, AURKA, AURKB, BCL2, BRAF, BRCA1, BRCA2, CDH1, CDK4, CDK6, CDKN2A, CSF1R, CTNNB1, DDR2, EGFR, EPHB4, ERBB2, ERBB3, ERBB4, EWSR1, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2, IGF1R, ITK, JAK1, JAK2, JAK3, KDR, KIT, KRAS, MDM2, MET, MLH1, MPL, MTOR, NF1, NOTCH1, NPM1, NRAS, NTRK1, PDGFRA, PDGFRB, PIK3CA, PIK3R1, PTCH1, PTCH2, PTEN, PTPN11, RB1, RET, ROS1, SMAD4, SMARCB1, SMO, SRC, STK11, SYK, TERT, TMPRSS2, TOP1, TP53*, and *VHL*. Additionally, some introns of the following five genes were included for the detection of gene fusions: ALK, RET, ROS1, EWSR1, and TMPRSS2 (SureSelect, Agilent, Inc., USA). Two hundred to 500 ng of genomic DNA extracted from FFPE of cancer patients was prepared to construct libraries using the SureSelect targeting panel according to the manufacturer\'s protocol. Briefly, genomic DNA samples were randomly fragmented by Covaris (Covaris, Inc., USA), followed by adapter ligation, purification, hybridization, and PCR. Captured libraries were analyzed in the Agilent 2100 Bioanalyzer to estimate the quality of nucleotides and were loaded onto the Illumina HiSeq2500 instrument (TheragenEtex Bio Institute, Suwon, Korea) according to the manufacturer\'s recommendations. Raw image files were processed in the HCS1.4.8 software for base-calling using default parameters, and the sequences of each individual were generated as 101-bp paired-end reads.

Analytical Methods {#s0025}
------------------

For NGS data preprocessing, sequence reads were aligned to the human genome (hg19) using BWA-MEM [@bb0025]. To generate the analysis-ready Binary Alignment Map (BAM), the overall preprocessing steps, including removal of duplicates, local realignment, and recalibration, were performed using GATK Best Practice (Broad Institute) [@bb0030]. For variant discovery (SNVs and INDELs), we used three open-source callers (UnifiedGenotyper [@bb0035], LoFreq [@bb0040], and SNVer [@bb0045]) and Samsung SDS\'s in-house callers. CNVs and translocations were discovered using in-house callers developed by Samsung SDS. SNVs and INDELs were filtered using germ-line mutations and false-positive filters. SNVs with variant allele frequency ≥5% and INDELs ≥10% were selected for this study. CNVs were analyzed using the depth of coverage for each target region between tumor and preprocessed normal data. To calculate absolute copy number, tumor purity and ploidy were estimated using a statistical model consisting of log~2~ ratio values and SNV variant allele frequency values. As a cutoff value, copy number (CN) ≥7 and CN = 0 were used for amplification and homozygous deletion, respectively. For detection of translocations, a paired-end mapping analysis and a split-alignment analysis were performed. All discordant read-pairs with abnormal insert size or orientation were screened, and soft-clipping information of the split-reads was investigated as evidence of genomic rearrangements. The confidence cutoff value for translocations was a split-read support count ≥3.

Site-Directed Mutagenesis and Transfection {#s0030}
------------------------------------------

A *KRAS* A146 mutation was engineered into the pLenti-C-mGFP-P2A-puro vector using the QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies, CA, USA) according to the manufacturer\'s instructions. The constructs were verified by Sanger sequencing. Lentivirus stocks were produced using the Virapower lentiviral packaging mix and the 293FT cell line according to the manufacturer\'s protocol (Invitrogen, CA, USA). HT29 cells were grown to 50% confluence and incubated for 24 hours in a 1:1 dilution of virus:media with 5 μg/ml Polybrene. After a 24-hour recovery period in complete media without virus, polyclonal stable cell lines were selected and maintained in media containing 5 μg/ml puromycin. Cells expressing green fluorescent protein were observed under the microscope, and mutations were verified by Sanger sequencing.

Measurement of Cell Viability {#s0035}
-----------------------------

Cell viability was evaluated using an MTT assay. After washing the cells, culture medium containing 0.5 mg/ml MTT was added to each well. The cells were incubated for 2 hours at 37°C, the supernatant was removed, and the formazan crystals formed in viable cells were solubilized with 0.11 ml of dimethylsulfoxide. A 0.1-ml aliquot of each sample was then transferred to 96-well plates, and the absorbance of each well was measured at 570 nm using a spectrophotometer (Hewlett-Packard, Agilent Technologies, USA). Data are expressed as a percentage of control measured in the absence of paclitaxel.

Western Blotting {#s0040}
----------------

Cells were harvested at various time points after paclitaxel treatment and disrupted in lysis buffer (1% Triton X-100, 1 mM EGTA, 1 mM EDTA, 10 mM Tris--HCl, pH 7.4, and protease inhibitors). Cell debris was removed by centrifugation at 10,000×*g* for 10 minutes at 4°C. The resulting supernatant proteins were separated using SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were blocked with 5% nonfat dried milk at room temperature for 30 minutes and incubated with anti-MEK, anti-ERK, anti-phosphorylated MEK, anti-phosphorylated ERK (Cell Signaling Technology, MA, USA), and anti-GAPDH. The membranes were then washed and incubated with horseradish peroxidase--conjugated secondary antibody. Signals were visualized using enhanced chemiluminescence (Amersham; Buckinghamshire, UK).

Results {#s0045}
=======

Patient Characteristics {#s0050}
-----------------------

For this study, we enrolled 25 refractory metastatic solid tumor patients treated with conventional treatments ([Figure 1](#f0005){ref-type="fig"}). FFPE samples from those patients were used for targeted sequencing and analyzed. Their baseline characteristics are described in [Table 1](#t0005){ref-type="table"}. The most common tumor types were uterine sarcoma (20%, *n* = 5) and breast carcinoma (16%, *n* = 4), followed by malignancy of undefined origin (MUO) (12%, *n* = 3), renal cell carcinoma (8%, *n* = 2), and neuroendocrine tumor (8%, *n* = 2). The median age at diagnosis was 51.9 years (range 22-72). Eighteen patients had metastatic disease at diagnosis.Figure 1Schematic representation of the study design. The process started with targeted sequencing using FFPE samples from 25 refractory cancer patients. All patients underwent genomic sequencing. The number of patients who actually received matched therapy according to genomic alterations was three.Figure 1Table 1Characteristics of the 25 Study PatientsTable 1CharacteristicsValueAge (year) Median51.9 Range22--72Sex Male6 Female19ECOG performance status score 013 18 23 31Metastatic disease at initial diagnosis18Received prior treatments (range, 1-6) 112 26 33 42 51 61Diagnosis Uterine sarcoma5 Breast carcinoma4 Malignancy or undefined origin3 Renal cell carcinoma2 Neuroendocrine tumor2 Cholangiocarcinoma1 Colon carcinoma1 Tongue carcinoma1 Leiomyosarcoma1 Liposarcoma1 Malignant peripheral nerve sheath tumor1 Pleomorphic myogenic sarcoma1 Cervical cancer1 Uterus neuroendocrine carcinoma1[^2]

Sequencing Results {#s0055}
------------------

All patients underwent genomic sequencing owing to the high DNA concentrations and tumor cellularity of samples. The median time from FFPE to completion and final analysis of NGS patient data was approximately 3-4 weeks. Mean coverage was 1840.98×, with 98.23% over 100× ([Supplemental Table 1](#ec0005){ref-type="supplementary-material"}). Six out of 25 cases had CNV in targetable genes. The most frequently detected amplifications were in *PDGFRB* ([Table 2](#t0010){ref-type="table"}). A translocation was detected in only one case, which was the ALK-EML fusion gene.

Molecularly Targeted Therapies {#s0060}
------------------------------

Among the 25 patients, seven patients had at least one molecular alteration matching one of the available targeted agents. However, targeted therapy was guided in only three patients (12%) on the basis of sequencing results because of lack of access to clinical trials (*n* = 1), declining clinical state and performance status (*n* = 2), and/or stable disease with previous treatment (*n* = 1) ([Figure 1](#f0005){ref-type="fig"}). Patient 1 with MUO had ALK-EML4 fusion and achieved partial response to crizotinib ([Table 3](#t0015){ref-type="table"}). Before crizotinib therapy, the patient received several individual regimens of chemotherapy including 5-fluorouracil/cisplatin and paclitaxel/cisplatin but finally progressed to all regimens. Patient 14 with uterine sarcoma had amplifications of *AKT3*, *BRAF*, and *EGFR* ([Table 3](#t0015){ref-type="table"}). He had multiple lung metastases. Adriamycin was initiated as a palliative chemotherapy. Subsequently, ifosfamide, gemcitabine, and docetaxel were administered as palliative therapy. Despite continual therapy, pulmonary metastasis progressed. On the basis of NGS test results, this patient was treated with everolimus for *AKT3* amplification. As shown in [Figure 2](#f0010){ref-type="fig"}, patient 14 showed clinical improvement with partial responses to everolimus. CT scans of patient 14 before and after everolimus-based therapy showed a decreased tumor size. Treatment was discontinued at 5 months after disease progression was confirmed.Table 2List of Drug-Targetable Alterations in Seven PatientsTable 2IDCancer TypeGeneMutation TypeTargeted DrugPatient 1MUOALK-EMLFusionCrizotinibPatient 4Uterine sarcoma*PDGFRB*CNV, amplificationSorafenibPatient 10Leiomyosarcoma*PDGFRB*CNV, amplificationSorafenibPatient 11Liposarcoma*AKT2*CNV, amplificationEverolimusPatient 14Uterine sarcoma*AKT3*CNV, amplificationEverolimusPatient 21Breast cancer*AKT1*CNV, amplificationEverolimusPatient 22Colon cancer*EGFR*\
*KRAS*CNV, amplification\
SNVBevacizumabTable 3Outcomes of Targeted TherapyTable 3Patient IDTumor TypeTargeted MutationOther MutationDrugBest ResponsePatient 1MUOALK-EML4 fusionCrizotinibPRPatient 14Uterine sarcoma*AKT3* amplification*BRAF*, *EGFR* amplificationEverolimusPR[^3]Figure 2CT scans from patient 14, a 62-year-old woman with uterine sarcoma treated with everolimus. The pretreatment CT image (left panel) shows multiple lesions. The follow-up CT image (right panel) was obtained after 3 months of everolimus treatment and shows decreased lesion size in multiple lesions.Figure 2

Mechanisms of Resistance to Targeted Therapies {#s0065}
----------------------------------------------

We also detected mutations associated with drug resistance. Patient 22 had wild-type *KRAS* codons 12 and 13 and *EGFR* amplification ([Table 4](#t0020){ref-type="table"}). He had been treated with a combination of cetuximab and folinic acid, fluorouracil, and irinotecan (FOLFIRI), based on the results of previous molecular diagnostic tests, but showed resistance to *EGFR*-targeted therapy. Targeted sequencing of the tumor from this patient revealed a *KRAS* A146V mutation, which has been shown to confer resistance to anti-EGFR therapy. Based on this result, he was treated with combined bevacizumab and folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and had a partial response. His CT scan images showed that the lesions of liver metastases that were increased after treatment with cetuximab and FOLFIRI significantly reduced in size after bevacizumab and FOLFOX therapy ([Figure 3](#f0015){ref-type="fig"}).Table 4Mechanism of Resistance to Targeted TherapyTable 4Patient IDTumor TypeTestTargeted MutationOther MutationDrugBest ResponsePatient 22Colon cancerMolecular Diagnostic test*EGFR* amplificationCetuximabPDTargeted Sequencing\
(NGS)*EGFR* amplification*KRAS*\
(A146V)BevacizumabPR[^4]Figure 3CT scans from patient 22, a 55-year-old man with liver metastatic colon cancer. The CT image (middle panel) after therapy with cetuximab and FOLFIRI shows increased prevalence of liver metastases compared to that in the pretreatment CT image (left panel). The follow-up CT image (right panel) obtained after therapy with bevacizumab and FOLFOX shows attenuation of liver metastases.Figure 3

Next, to investigate the role of the *KRAS* A146V mutation in the resistance of colon cancer cells to anti-EGFR therapy, we used HT29 cells that did not harbor any activating *KRAS* mutations. HT29 cells were transfected with a lentiviral vector expressing the *KRAS* A146V mutation, as well as other well-known *KRAS* 146 mutations (A146T or A146P); the mutations were confirmed by Sanger sequencing ([Figure 4](#f0020){ref-type="fig"}*A*). Cell viability was higher in HT29 cells with *KRAS* A146V and A146T mutations after cetuximab treatment than in cells expressing wild-type *KRAS* and in control cells ([Figure 4](#f0020){ref-type="fig"}*B*). Moreover, to study the response of *KRAS*-mutant cells to *MEK* inhibition, we examined cell viability after treatment of *KRAS*-mutant cells with PD98059, an inhibitor of *MEK1/2*. [Figure 4](#f0020){ref-type="fig"}*C* shows that *KRAS*-mutant cells (A146V or T) were insensitive to PD98059. Together, these results suggest that colon cancer cells with the *KRAS* A146V mutation are resistant to cetuximab and *MEK* inhibition.Figure 4Resistance to *EGFR* or *MEK*-targeted drugs in *KRAS*-mutant HT-29 cells. (A) Vectors expressing *KRAS* A146V, P, T, or wild type were introduced into HT-29 cells through lentiviral infection. Mutations were confirmed by Sanger sequencing. HT-29 cells expressing *KRAS* wild type, A146V, A146P, or A146T were treated with the indicated concentration of cetuximab (B) or PD98059 (C) for 24 hours. An MTT assay was performed to measure cell viability. Experiments were repeated three times, each with three replicates. Error bars indicate SEM.Figure 4

Discussion {#s0070}
==========

The use of NGS testing for clinical application has been spreading rapidly worldwide. The present pilot study was conducted to explore the feasibility of employing NGS-guided therapy in patients with refractory solid tumors. In this study, seven of 25 (28%) patients had molecular alterations matching one of the available targeted drugs. Of these, only three patients (12%) were enrolled in the genome-based clinical trial. In another pilot study in Korea, only a small number of patients (15%, 5/32) received NGS-based targeted therapy [@bb0050]. Although most patients were expected to have at least one drug-targetable mutation in their tumors, limiting factors included a lack of patient participation in clinical trials, poor performance status, and stable disease following previous treatment [@bb0050]. Access to trials and use of off-label drugs depend on the financial status of patients. To promote genome-based clinical trials, issues such as the lack of access to clinical-grade NGS testing and the limited number of targeted drugs must be resolved [@bb0050]. Most importantly, cancer patients need to be referred for possible clinical trial enrollment before their performance status deteriorates [@bb0055]. Thus, physicians must be encouraged to check patient availability for participation in trials. In addition, earlier NGS testing is needed so that more patients can receive targeted therapy.

It is reported that the main reason for failure of NGS testing is low cellularity and low DNA content in samples [@bb0060], [@bb0065]. We extracted DNA from a tumor region marked with a circle on the FFPE slide by the pathologist to enrich tumor cells. All patients enrolled in this study underwent successful NGS testing owing to sufficient amounts of DNA. Moreover, a high read depth is required for detection of variants of low frequency. In this study, the average coverage was 1840.98X, with 98.23% of the targeted base covered at over 100×. However, the turnaround time for testing took 3 to 4 weeks in this study. Faster turnaround times may help to better treat cancer patients.

Although only three patients received targeted therapy, the present study showed that NGS-based targeted therapy benefited the patients with refractory cancer. Partial response was achieved in all three patients receiving targeted therapy. The MUO patient with ALK-EML4 fusion received *ALK* inhibitor crizotinib treatment; however, this patient was not followed up because he transferred to another hospital. The uterine sarcoma patient with amplification of *AKT3* was treated with everolimus, which targets *mTOR* downstream of *PI3KCA* and *AKT.* In addition, the colon cancer patient with wild-type *KRAS* codons 12 and 13 and *EGFR* amplification had been receiving a combination therapy of cetuximab and FOLFIRI prior to NGS testing. After the cancer relapsed, NGS testing was conducted using his tumor tissue, and the *KRAS* A146V mutation (which is known to cause resistance to cetuximab) was found. He then received a combination therapy of bevacizumab and FOLFOX, and showed partial response. These results are supported by clinical data suggesting that the use of bevacizumab (an anti-VEGF drug) after cetuximab-based treatment is effective [@bb0070]. Moreover, they are also supported by a previous preclinical study suggesting that anti-EGFR therapy--resistant colorectal cancer (CRC) cells upregulate *VEGF* levels and respond to antiangiogenic drugs [@bb0075].

*KRAS* mutations are found in about 30% to 50% of CRC patients, and the most frequent mutations are detected in approximately 40% of CRC patients in codons 12 and 13 [@bb0080], [@bb0085], [@bb0090]. Those are known as predictors of resistance to anti-EGFR therapy; therefore, *KRAS* mutation testing is necessary prior to administration of anti-EGFR therapy in CRC patients. Currently, *KRAS* codon 61 and 146 mutations have a frequency of 1%-4% and show resistance to anti-EGFR therapy in wild-type *KRAS* codon 12 and 13 patients [@bb0095]. In the case of patient 22, the *KRAS* codon 146 mutation, which was not included in prior *KRAS* mutation tests, was detected by NGS testing. The results highlighted the limitation of *KRAS* hotspot mutation testing and suggested that NGS testing is sufficient and necessary for detecting multiple mutations and for refractory cancer patients with low-frequency mutations.

*KRAS* 146 codon mutations, such as c.436G\>A p.A146T, c.436G\>C p.A146P, and c.437C\>T p.A146V, were found in CRC [@bb0095]. In the present study, the A146V *KRAS* mutation was identified in the CRC patient with wild-type codons 12 and 13. Although clinical data have shown that those *KRAS* 146 mutations are associated with resistance to *EGFR*-targeted therapy (cetuximab) in CRC patients [@bb0100], [@bb0105], the molecular mechanism underlying the association of therapy resistance and those mutations is not well known. Janakiramam et al. reported that the *KRAS* A146T mutation increased RAS activity, and *KRAS* A146T-expressing xenografts were resistant to *EGFR*-targeted inhibition and sensitive to *MEK* inhibition [@bb0110]. However, the efficacy of *MEK* inhibitors in colon cancer patients with *KRAS* mutations has been modest [@bb0115], [@bb0120]. Consistent with this, *MEK* inhibition was ineffective in *KRAS*-mutant cells, even though our *in vitro* studies showing cell death inhibition in *KRAS*-mutant cells treated with cetuximab support that the *KRAS* A146V mutation is a predictor of resistance to *EGFR*-targeted inhibitors. These results demonstrate that *MEK* is not the key downstream pathway in those cells. In addition, our study showed that *KRAS* A146P mutant cells were sensitive to *EGFR* or *MEK* inhibitors, in contrast to cells with *KRAS* A146T/V. The characteristics of *KRAS* 146 mutations need to be elucidated further for the development of additional treatment options.

In the present study, we showed that NGS testing using a cancer gene panel allowed us to match patients to targeted therapies and provided shorter timelines for clinical trials than did those for testing single biomarkers. Although a very small number of patients were enrolled, our results demonstrate the feasibility and reliability of NGS testing for targeted therapies in refractory cancer patients, which may potentially help more patients achieve better outcomes. Recently, the clinical application of NGS has started under the medical insurance system in South Korea. This will increase NGS testing rates and also give physicians more options to better manage cancer patients with relevant mutations. Further functional studies on genetic variants will help elucidate their pathogenic role, which may have important clinical implications.

The following are the supplementary data related to this article.Supplementary Table 1Sequencing QC.Supplementary Table 1

Funding:This study was supported by Busan Cancer Center Research Grant (2018), Pusan National University Hospital, Republic of Korea.

Declarations of Interest: None.

[^1]: These authors contributed equally.

[^2]: *ECOG*, Eastern Cooperation Oncology Group.

[^3]: *PR*, partial response.

[^4]: *PD*, progressive disease; *PR*, partial response.
